Chugai Implements Genedata Profiler to Accelerate Data-driven Biomarker Discovery
Genedata Profiler used for biomarker discovery and validation projects in support of Chugai’s early proof of concept research initiatives
Tokyo, Japan – March 10, 2020 – Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Chugai Pharmaceutical Co., Ltd., a leading research-based pharmaceutical company in Japan, has chosen Genedata Profiler® as one of the cornerstones of their biomarker strategy to support the efficient identification and validation of innovative, next-generation biomarkers.
“We chose Genedata Profiler because it is the end-to-end enterprise software able to harmonize our dispersed data analysis pipelines”, said Kimio Terao, Department Manager of Clinical Pharmacology at Chugai. “We need to enhance our capacity to analyze large amounts of high-dimensional ‘omic data emerging from our rapidly growing number of translational and clinical research projects. This requires domain-specific software to automate the processing, analysis, and integration of such complex molecular data types. We needed a solution that scales with us as we grow. And Genedata, who impressed us with their tremendous scientific expertise, provided this.”
Genedata Profiler is now integrated into Chugai’s data analysis pipeline and will support the company achieve ‘early Proof of Concept’, ultimately bringing innovative drugs to patients faster. Set up as a cloud-based system that is fully scalable, Genedata Profiler helps Chugai cope with the massive increase in data volume and complexity of their clinical and translational research projects. In addition, multiple levels of fine-grained access control ensure data security throughout the entire data lifecycle. And since the advanced exploratory analytics of Genedata Profiler don’t necessarily require programming skills, Chugai’s translational researchers can easily and rapidly deliver high-quality results. This holistic, data-driven approach will empower Chugai to accelerate the discovery of innovative biomarkers and will lead to a rising number of successful R&D projects.
“We are excited to enable Chugai to increase the efficiency of their R&D processes”, said Othmar Pfannes, Ph.D., CEO of Genedata. “Genedata Profiler has been successful in Europe and the US for years. The fact that a leading global biopharma company from Japan is now implementing Genedata Profiler is an important milestone in our global expansion strategy and further confirms the quality of our product. A part of our Biopharma Platform, Genedata Profiler supports our customers bring pioneering therapeutics to patients faster, so that they can live better and longer lives. We are committed to continuing to invest in the development of the Genedata Biopharma Platform to provide our customers with an enterprise workflow platform that will help them digitalize R&D to increase their speed to market.”
About Chugai Pharmaceutical
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
Phone: +41 61 511 85 61
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.